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Myeloproliferative Disorders
Introduction
The characterization of the genetic background of BCR-
ABL1-negative chronic myeloproliferative neoplasms (MPN)
was greatly advanced by the discovery that the V617F muta-
tion of Janus kinase 2 (JAK2) is very common in the three clas-
sic MPN, occurring in 90-95% of cases of polycythemia vera
(PV), and in 40-60% of cases of essential thrombocythemia
(ET) and primary myelofibrosis (PMF).1-4 This led to the inclu-
sion of V617F mutation screening in the diagnostic criteria for
MPN.5 JAK2 exon 12 mutations occur in rare cases of V617F-
negative PV allowing a close to perfect coverage by specific
genetic alterations in PV.6,7 On the other hand, clinicians con-
tinue to face challenges during the diagnosis of JAK2 muta-
tion (JAK2mut)-negative ET and PMF. Moving the field very
close to full coverage, in two parallel seminal discoveries,
Klampfl et al.8 and Nangalia et al.9 recently described somatic,
recurrent insertions/deletions exclusively affecting exon 9 of
the calreticulin (CALR) gene. Affecting the same driver path-
way, CALR mutations were mutually exclusive with JAK2
V617F or myeloproliferative leukemia virus oncogene gene
(MPL) mutations. In a plethora of subsequent studies pub-
lished within 3 months, the initial findings were confirmed
and extended focusing on the clinical correlates.10-13 Several
additional studies described low frequencies of CALR muta-
tions in different MPN-related diseases, but not in other
hematologic diseases.8,9,14-18
As a result of the discovery of CALR mutations, definite
molecular diagnostics have become available for 75-90% of
clonal MPN. However, for the introduction of CALRmutation
screening into routine clinical practice, it is essential to char-
acterize the potential effects of CALR mutations on disease
phenotype and progression in several independent cohorts.
The aim of our study was to apply a complex array of molec-
ular techniques to identify driver mutations. We aimed to
confirm previous associations between the presence of
acquired genetic alterations and clinical characteristics in a
large, independent cohort of patients with MPN. An addition-
al purpose was to systematically analyze the roles of particu-
lar CALR mutation types and load.
Methods
Subjects
Our study population consisted of 603 patients with BCR-ABL1-
negative MPN (260 males, 343 females; median age: 60, range: 10-94
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Somatic insertions/deletions in the calreticulin gene have recently been discovered to be causative alterations in
myeloproliferative neoplasms. A combination of qualitative and quantitative allele-specific polymerase chain reac-
tion, fragment-sizing, high resolution melting and Sanger-sequencing was applied for the detection of three driver
mutations (in Janus kinase 2, calreticulin and myeloproliferative leukemia virus oncogene genes) in 289 cases of essen-
tial thrombocythemia and 99 cases of primary myelofibrosis. In essential thrombocythemia, 154 (53%) Janus kinase
2 V617F, 96 (33%) calreticulin, 9 (3%) myeloproliferative leukemia virus oncogene gene mutation-positive and 30
triple-negative (11%) cases were identified, while in primary myelofibrosis 56 (57%) Janus kinase 2 V617F, 25 (25%)
calreticulin, 7 (7%) myeloproliferative leukemia virus oncogene gene mutation-positive and 11 (11%) triple-negative
cases were identified. Patients positive for the calreticulin mutation were younger and had higher platelet counts
compared to Janus kinase 2 mutation-positive counterparts. Calreticulin mutation-positive patients with essential
thrombocythemia showed a lower risk of developing venous thrombosis, but no difference in overall survival.
Calreticulin mutation-positive patients with primary myelofibrosis had a better overall survival compared to that of
the Janus kinase 2 mutation-positive (P=0.04) or triple-negative cases (P=0.01). Type 2 calreticulin mutation occurred
more frequently in essential thrombocythemia than in primary myelofibrosis (P=0.049). In essential thrombo-
cythemia, the calreticulin mutational load was higher than the Janus kinase 2 mutational load (P<0.001), and
increased gradually in advanced stages. Calreticulin mutational load influenced blood counts even at the time point
of diagnosis in essential thrombocythemia. We confirm that calreticulin mutation is associated with distinct clinical
characteristics and explored relationships between mutation type, load and clinical outcome.
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years) diagnosed between 1974 and 2013, as an extension of those
published earlier.19,20 According to World Health Organization
2008 criteria, 215 patients had JAK2V617F positive PV, 289 had ET
and 99 had PMF. Laboratory parameters and clinical features at the
time of diagnosis were collected retrospectively. Coagulation com-
plications and myelofibrotic or acute leukemic transformation
were recorded if they were present at diagnosis or occurred during
the follow-up. Coagulation complications included venous throm-
botic events (deep vein thrombosis, pulmonary embolism,
splanchnic or cerebral venous thrombosis), arterial thrombosis
(transient ischemic attack, ischemic stroke, acute myocardial
infarction, or peripheral arterial vascular complications) and hem-
orrhagic problems (gastrointestinal bleeding, hemorrhagic stroke,
hematuria, severe bleeding during surgery or dental procedures).
The median follow-up was 5.7 years (range, 0-40 years). All par-
ticipants signed informed consent. The study was approved by the
Hungarian National Ethics Committee.
Detection of driver somatic mutations
All analyses were performed using genomic DNA isolated from
peripheral blood or bone marrow. In a subset of patients, sampling
and diagnostic ascertainment occurred within 1 year. In some
analyses, these cases were considered separately as the ones best
reflecting the patients’ condition at diagnosis.
All MPN patients were screened for JAK2 V617F (c.1849G>T)
by allele-specific polymerase chain reaction (PCR).1 In JAK2mut
cases, real-time quantitative PCR was performed to determine the
V617F load.21 The JAK2mut load was calculated as follows:
JAK2mut/(JAK2mut+JAK2wild-type).
JAK2mut-negative ET and PMF patients were screened for CALR
mutations by high resolution sizing of fluorescence-labeled PCR
products by capillary electrophoresis (fragment analysis).8 In
CALRmut cases, the precise mutation was identified by Sanger-
sequencing.8 To determine the mutant load, the ratio of peak
heights was calculated using an analogous formula:
CALRmut/(CALRmut+CALRwild-type). Since fragment analysis was a
semi-quantitative approach and the final amounts of the PCR
products were influenced by the preferential amplification of
shorter amplicons, we calculated the load after PCR with 25
cycles, which was a reduced cycling condition compared to the
screening condition (35 cycles).
In JAK2mut and CALRmut negative ET and PMF patients, screening
for MPL S505N and W515 codon mutations was performed by
high resolution melting analysis.22 In cases that were positive in
this screening analysis, the exact type of MPLmutation was deter-
mined by allele-specific PCR and sequencing.23
Statistics
Continuous variables are presented as medians with 25th and
75th percentiles. Mann-Whitney or Kruskal-Wallis tests were used
to compare continuous variables, while χ2 or Fisher exact tests
were used for dichotomous variables. A log-rank test was per-
formed to compare overall survival between subgroups according
to driver mutations. In the case of hematopoietic stem cell trans-
plantation (n=13), the follow-up period was terminated at the date
of the transplant. For multivariate analysis, age was considered in
a Cox proportional hazards model beside driver mutations.
Hazard ratios (HR) and 95% confidence interval (CI) values were
computed. The analyses were conducted using the SPSS (version
20.0) software package.
Results
Distribution of different types of driver mutations 
and comparisons of clinical parameters in subgroups
according to driver mutation status
Only JAK2 V617F positive (JAK2mut) PV patients (n=215)
were included in this study. In patients with PV, qualita-
tive and quantitative JAK2 V617F tests, but no CALR and
MPL molecular tests, were performed. For ET, the distri-
bution of driver mutations was as follows: JAK2mut:
154/289 (53%), CALRmut: 96/289 (33%), MPLmut: 9/289
(3%), triple-negative: 30/289 (11%) cases (Table 1). For
PMF, the corresponding figures were: JAK2mut: 56/99
(57%), CALRmut: 25/99 (25%), MPLmut: 7/99 (7%), triple-
negative: 11/99 (11%) cases (Table 2).
The patients’ clinical and laboratory parameters were
systematically compared according to diagnosis and driver
mutation. Given the low number of cases, patients with
MPLmutation were omitted from all subsequent analyses.
Compared to the JAK2mut PV cohort, the JAK2mut ET cohort
contained more females (P<0.001), had lower hemoglobin
levels (P<0.001), higher platelet counts (P<0.001), less fre-
quent splenomegaly (P<0.001) and less frequent myelofi-
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Table 1. Clinical and laboratory characteristics of PV and ET patients according to the presence of a driver somatic mutation.
(A) (B) P (C) P (D)
PV ET, JAK2mut (A) vs. (B) ET CALRmut (C) vs. (B) ET, triple neg.
(n=215) (n=154) (n=96) (n=30)
Age, year (25th-75th percentile) 61 (51-70) 61 (51-71) 0.975 53 (37-70) 0.025 60 (43-67)
Male/female (%/%) 113/102 (53%/47%) 46/108 (30%/70%) <0.001 39/57 (41%/59%) 0.099 8/22 (27%/73%)
Hemoglobin (g/L, 25th-75th percentile) 183 (173-199) 147 (134-156) <0.001 131 (120-145) <0.001 130 (120-138)
WBC (109/L, 25th-75th percentile) 11 (9-13) 10 (8-13) 0.574 9 (8-12) 0.034 10 (8-13)
PLT (109/L, 25th-75th percentile) 456 (315-619) 778 (651-992) <0.001 981 (767-1389) <0.001 791 (632-1016)
Splenomegaly, n. (%) 96/204 (47%) 37/139 (27%) <0.001 20/74 (27%) 1.00 5/23 (22%)
Venous thrombosis, n. (%) 28/215 (13%) 27/153 (18%) 0.237 6/85 (7%) 0.03 2/28 (7%)
MF transformation, n. (%) 28/215 (13%) 9/153 (6%) 0.034 13/87 (15%) 0.034 1/29 (3%)
AL transformation, n. (%) 16/212 (8%) 4/154 (3%) 0.06 3/88 (3%) 1.00 0/29 (0%)
Cytoreduction, n. (%) 140/160 (87%) 98/123 (80%) 0.107 62/82 (76%) 0.496 17/20 (85%)
ET-patients qualified for triple-negative status (D) if no JAK2mut or CALRmut or MPLmut was present. Clinical and laboratory data apply at the time of first presentation. Cytoreduction
was defined positive if hydroxyurea or anagrelide treatment was given for more than 6 months. P values below 0.05 were considered statistically significant and are indicated in
bold. AL: acute leukemia; ET: essential thrombocythemia; Hb: hemoglobin concentration; MF: myelofibrotic, PLT: platelet count; PMF: primary myelofibrosis; PV: polycythemia vera;
WBC: white blood cell count.
brotic transformation (P=0.034) (Table 1). Compared to
the JAK2mut ET cohort, in the CALRmut ET patients we
found a tendency toward less pronounced female predom-
inance (P=0.099), younger age at diagnosis (P=0.025),
lower hemoglobin levels (P<0.001), lower white blood cell
counts (P=0.034) and higher platelet counts (P<0.001).
Coagulation complications (venous and arterial throm-
boses, plus hemorrhages, taken together) were more fre-
quent in JAK2mut ET patients (36%, 55/153) than in CALRmut
ET patients (18%, 15/85; P=0.003). Venous thrombosis
was more frequent in JAK2mut ET than in CALRmut ET
(P=0.03). Arterial thrombosis occurred in 14% (22/153) of
JAK2mut and in 9% (8/85) of CALRmut ET (P=0.3), and hem-
orrhage in 9% (14/153) of JAK2mut and in 5% (4/85) of
CALRmut ET (P=0.3). Myelofibrotic transformation
occurred more frequently in the CALRmut cohort (P=0.03).
We did not find any significant differences comparing
triple-negative ET patients to other ET subgroups: the
sample size (n=30) was, however, small.
Similar analyses in the PMF cohort (Table 2) showed
younger age at presentation (P=0.002) and higher platelet
counts (P=0.001) in the CALRmut subgroup than in the
JAK2mut PMF subgroup. Other variables were not different,
nor were any of the characteristics of the triple-negative
PMF patients except for an increased rate of acute
leukemic transformation in triple-negative cases (36% ver-
sus 9% in JAK2mut, P=0.038 or versus 14% in CALRmut,
P=0.19).
Regarding outcome parameters, overall survival was
analyzed, initially by a univariate Kaplan-Meier approach,
in patients with ET (Figure 1A) and PMF (Figure 1B) strat-
ified according to different driver mutations. Out of the
289 ET patients, 261 cases had appropriate follow-up
information [JAK2mut (n=150), CALRmut (n=85) and triple-
negative (n=26) subgroups]. As shown in Figure 1A, no
differences were detected in overall survival by univariate
analyses (P=0.846). 
Among PMF patients (n=87), the subgroups were as fol-
lows: JAK2mut (n=55), CALRmut (n=21) and triple-negative
(n=11). In contrast to ET, the overall comparison resulted
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Table 2. Clinical and laboratory characteristics of PMF patients according to the presence of a driver somatic mutation.
                                                                                      (A)                                            (B)                                        P                                     (D)
                                                                              PMF, JAK2mut                             PMF, CALRmut                         (A) vs. (B)                     PMF, Triple neg.
                                                                                   (n=56)                                      (n=25)                                                                         (n=11)
Age, year (25th-75th percentile)                                          68 (57-73)                                        56 (39-65)                                      0.002                                    69 (53-79)
Male/female (%/%)                                                        28/28 (50%/50%)                             12/13 (48%/52%)                                  1.00                                 8/3 (72%/27%)
Hemoglobin (g/L, 25th-75th percentile)                          116 (58-183)                                    112 (97-124)                                    0.484                                   95 (79-121)
White cell count (109/L, 25th-75th percentile)                  12 (8-18)                                           9 (5-13)                                        0.147                                     12 (7-25)
Platelet count (109/L, 25th-75th percentile)                   250 (132-500)                                  552 (320-712)                                   0.001                                 156 (54-452)
Splenomegaly, n. (%)                                                         47/56 (84%)                                     14/21 (67%)                                     0.120                                   9/11 (82%)
Venous thrombosis, n. (%)                                               9/54 (17%)                                        1/21 (5%)                                       0.266                                    1/11 (9%)
AL-transformation, n. (%)                                                  5/54 (9%)                                        3/22 (14%)                                      0.684                                   4/11 (36%)
Cytoreduction, n. (%)                                                        30/43 (70%)                                      9/17 (53%)                                      0.243                                    6/8 (75%)
For explanation and abbreviations see Table 1.
Figure 1. Kaplan-Meier analysis of overall survival in patients with ET (panel A, n=261) and PMF (panel B, n=87) according to the presence of
different driver mutations. Patients qualified for triple-negative status if JAK2mut and CALRmut and MPLmut were all absent. For a subset of
patients (ET: n=2, PMF: n=11) treated by hematopoietic stem cell transplantation, the follow-up was censored at the date of this intervention.
In ET, univariate analyses resulted in an overall P value of 0.846 (A). In PMF, the same comparison gave a P value of 0.023 (B). Upon pairwise
univariate comparisons, the CALRmut subgroup showed significantly better survival compared to JAK2mut (P=0.04) and triple-negative (P=0.01)
PMF patients while JAK2mut patients showed only a tendency towards better overall survival compared to triple-negative patients (P=0.076).
ET: essential thrombocythemia; PMF: primary myelofibrosis.
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in P=0.023 (Figure 1B) with the best overall survival in the
CALRmut subgroup and the worst in the triple-negative sub-
group. This was further confirmed by pairwise univariate
comparisons, namely CALRmut versus JAK2mut (P=0.04) and
CALRmut versus triple-negative (P=0.01). The JAK2mut PMF
patients showed only a tendency towards having a better
overall survival than the triple-negative patients (P=0.076).
To further analyze the potential effect of driver mutations
on survival, we utilized a Cox proportional hazard model
choosing the triple-negative PMF subgroup as the refer-
ence. In this model, age was a factor that significantly
affected survival (HR 1.082, 95% CI: 1.023-1.144;
P=0.006), while the presence of a driver mutation showed
an overall tendency (P=0.059). Performing pairwise com-
parisons, the CALRmut subgroup was characterized by a
HR=0.131 (95% CI: 0.023-0.739; P=0.021) indicating a sig-
nificantly better survival than that of triple-negative
patients. Comparing the CALRmut patients to the JAK2mut
subgroup, only a tendency towards better survival was
observed in the presence of CALR exon 9 mutation
(HR=0.159, 95% CI: 0.018-1.391; P=0.097).
Subgroup analyses in patients with CALRmut according
to type of mutation
Following fluorescence PCR and fragment analyses by
capillary electrophoresis, the presence of CALR exon 9
mutation was confirmed by Sanger-sequencing. In the
entire cohort of 121 CALR-positive cases, we found 64
(53%) with a type 1 mutation (52 base pair deletion,
c.1092_1143del), 34 (28%) with a type 2 mutation (5 base
pair insertion, c.1154_1155insTTGTC) and 23 (19%) with
other types of mutations. These other mutations com-
prised the following types: 3 (c.1095_1140del), 4
(c.1102_1135del), 5 (c.1091_1142del), 19 (c.1110_1140del),
22 (c.1120_1123del), 24 (c.1120_1138del), 29
(c.1135_1152delinsCCTCCTCTTTGTCT), 33
(c.1154_1155insATGTC), 34 (c.1154_delins CTTGTC), 35
(c.1154delinsTTTGTC) and potentially novel variants
(n=8). The occurrence of these variants according to diag-
nosis was as follows: ET: type 1: 48 (50%), type 2: 31
(32%) and other: 17 (18%); PMF: type 1: 16 (64%), type 2:
3 (12%) and other: 6 (24%). Comparing patients with ET
and PMF and only considering types 1 and 2, we found a
tendency to a different distribution with 48 type 1 (61%)
and 31 type 2 (39%) mutations in patients with EF versus
16 type 1 (84%) and 3 type 2 (16%) in patients with PMF
(P=0.064). An increased frequency of type 2 mutations
(versus non-type 2 mutations) was observed in ET (32%)
compared to PMF (12%, P=0.049, Online Supplementary
Table S1).
Next, we compared demographic and clinical parame-
ters within patients with CALRmut ET according to muta-
tion types. We found a tendency towards older age among
type 2 carriers compared to type 1 carriers (median age at
diagnosis: 59 years versus 51 years, P=0.06) or compared to
non-type 2 carriers (median age at diagnosis: 59 years ver-
sus 51 years, P=0.09). Similarly, platelet count at diagnosis
tended to be higher in the subgroup of type 2 mutation
carriers than in patients with the type 1 mutation:
1237x109/L (25th-75th percentile: 884-1472) versus 946
x109/L (25th-75th percentile: 764-1280) (P=0.081); or com-
pared to those with non-type 2 mutation: 865x109/L (25th-
75th percentile: 755-1218) (P=0.041). The frequency of
cytoreductive therapy was higher among type 2 versus
type 1 ET patients (89% versus 67% P=0.05). No further
differences in any demographic or clinical characteristics
(including overall survival) were found upon comparing
the two ET subgroups with different types of mutations
(Online Supplementary Table S2). Similar analyses were not
feasible for the PMF cohort because of the low number
(n=3) of patients with the type 2 CALR mutation.
Subgroup analyses in patients with a positive driver
mutation (JAK2mut or CALRmut) according to mutational
load
A systematic comparison was performed between MPN
subgroups in relation to the quantity of driver mutation
(Figure 2). The JAK2 V617F load was determined by real-
time quantitative allele-specific PCR using the TaqMan
detection system,21 while the semi-quantitative estimation
of the CALR mutation was achieved by high resolution
sizing of fluorescence-labeled PCR products.8 The muta-
tional load in JAK2 V617F and CALR mutation-positive
patients was calculated with a similar formula i.e. the
quantity of mutant was expressed as a percentage fraction
of total gene copies allowing the comparison of loads
across MPN subgroups with different mutations.
Performing pairwise comparisons, we made the following
observations (Figure 2). (i) Neither JAK2mut, nor CALRmut ET
patients without myelofibrotic transformation at the sam-
pling time showed significantly different driver mutation-
al loads comparing the subgroup of patients whose sam-
ples were taken within 1 year of diagnosis and the sub-
Calreticulin mutations in MPN
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Figure 2. Comparisons of relative quantities of driver mutations
(JAK2 V617F or CALR) in different MPN subgroups according to diag-
nosis and the relation of time of sampling and time of diagnosis. The
first row under the x axis shows the number of patients (n) in the
respective subgroups. If no primary or secondary myelofibrosis was
present at the time of sampling, sampling within 1 year of diagnosis
qualified, as seen in the second lines, as “<1 year”; all other situa-
tions were allocated into the “>1 year” subgroup. If primary or sec-
ondary myelofibrosis was present at the time of sampling, no such
subgrouping was performed (“secondary or primary MF”).
Quantification of the respective driver mutation was performed by
real-time quantitative allele-specific PCR (JAK2 V617F) or fragment
analysis (CALR exon 9). Pairwise comparisons were performed with
the Mann-Whitney test. ET: essential thrombocythemia; PMF: pri-
mary myelofibrosis; MF: myelofibrosis; PV: polycythemia vera.
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group of patients whose samples were taken at a later
time point. On the other hand, the two PV-subgroups (44
patients with sampling within 1 year of diagnosis and 140
patients with sampling at later time points but without
myelofibrotic transformation at this later time point)
showed a tendency toward increasing allele burden
(P=0.066). (ii) JAK2 loads increased gradually in parallel
with the appearance of more advanced stages of MPN
(JAK2mut ET versus PV: P<0.001, PV versus post-PV myelofi-
brosis: P<0.001). (iii) Within patients with ET, the CALR
load was significantly higher than the JAK2 load
(P<0.001). (iv) CALR load showed a steady, significant, but
less steep increase corresponding to the appearance of
more advanced MPN stages (CALRmut ET versus CALRmut
post-ET MF: P=0.01; CALRmut ET versus CALRmut PMF:
P<0.001). (v) In contrast to JAK2mut load, the CALRmut load
only rarely exceeded 50% (in 11 cases between 51-75%
and in 1 case above 75%).
To investigate the potential effects of CALR mutational
load, we divided CALRmut ET patients with samples avail-
able within 1 year after diagnosis (n=31) into two sub-
groups according to CALRmut load, with the cut-off value
being 38.5%, which was the median CALR mutational
load of all patients with ET in the study (n=20 below the
cut off and n=11 above the cut off; Table 3). White blood
cell counts (9 versus 11x109/L, P=0.025) and platelet counts
(848 versus 1406x109/L, P=0.04) were lower among
patients with low CALRmut load, while hemoglobin con-
centration was higher in the same comparison (138 versus
122 g/dL, P=0.04). Applying different cut-off values to dis-
criminate between groups with lower and higher CALRmut
burden, white blood cell counts were always lower in sub-
groups with lower CALRmut burden, although the differ-
ences shrank between the lower and the higher CALRmut
burden subgroups applying higher cut-offs. While the dif-
ferences in hemoglobin levels between patients with
lower and higher CALRmut load were only detectable above
the cut-off value of 38.5% or higher, the differences in
platelet counts diminished above this cut-off. We
observed higher CALRmut burden in type 1 (n=14, 41%)
compared to type 2 ET (n=15, 27%, P=0.023). However,
this difference may have been influenced by the preferen-
tial amplification of the shorter fragment in the presence
of the type 1 mutant (52 base pair deletion) during PCR,
thus this observation needs to be confirmed with an alter-
native technique of quantification.
Discussion
We set up sequential application of different molecular
techniques to identify the driver mutations in a large
cohort of MPN patients, noting that JAK2 V617F, CALR
and MPL mutations were described as mutually exclusive
driver mutations in the first studies.8,9 Concurrent JAK2
and CALR mutations were reported in only two individu-
als in subsequent studies.13,14 Confirming earlier observa-
tions in different MPN cohorts,8-10,13 we found a similar fre-
quency of CALR mutations in an independent group of
MPN patients, with the frequency of these mutations
being high (121/162, 75%) among JAK2 V617F and MPL-
negative ET patients, thus leaving only a small cohort of
triple-negative patients lacking a disease-causing genetic
marker.
In our previous study comparing the clinical characteris-
tics of JAK2mut and JAK2neg MPN patients (n=328),19 we
already noted a female predominance, older age at presen-
tation, higher hemoglobin values and a higher incidence of
coagulation complications (thrombotic and hemorrhagic)
in JAK2 V617F-positive MPN patients versus V617F-nega-
tive counterparts (including CALRmut patients). The identi-
fication of the CALRmutation allowed a more straight for-
ward comparison of MPN patients with a homogeneous
genetic background. Our present data, showing distinct
clinical characteristics of CALRmut ET subgroups in compar-
ison with JAK2mut cohorts, confirmed previous observa-
tions regarding younger age, sex distribution with less
prominent female abundance (only in the ET subgroup),
lower hemoglobin concentration, lower white blood cell
counts (not significant in our PMF cohort), and higher
platelet counts.8-12
Considering venous thrombosis and other coagulation
complications, our observations confirmed previous find-
ings describing a lower risk of thrombosis in patients with
CALRmut ET than in those with JAK2mut ET.8 In their extend-
ed cohort, Rumi et al.12 found that the rates of thrombosis
at diagnosis in the CALRmut and JAK2mut groups were 2.8%
and 7.1%, respectively (P=0.059), and observed a reduced
cumulative incidence of thrombosis (25 versus 10 events
per 1000 person-years) in CALRmut patients (P=0.001). In an
independent series of patients with ET, Rotunno et al.
found that the incidence of thrombosis (in the 2 years pre-
ceding diagnosis and during follow-up, combined) was
13.5% in their CALRmut cohort compared to 30.1% among
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Table 3. Laboratory characteristics of ET patients according to the CALR mutational load.
CALR mutational load
Cut-off 34.6% 38.5% 40.1%
Below Above Below Above Below Above
Number 17 14 20 11 22 9
Hemoglobin (g/L, 25th-75th percentile) 136 (127-143) 130 (116-151) 138 (130-154) 122 (105-141) 138 (131-147) 120 (100-158)
P=0.47 P=0.04 P=0.018
White cell count (109/L, 25th-75th percentile)8 (6-11) 11 (9-16) 9 (7-11) 11 (9-18) 9 (7-11) 11 (9-18)
P=0.005 P=0.025 P=0.046
Platelet count (109/L, 25th-75th percentile)828 (707-1099) 1319 (849-1669) 847 (706-1210) 1406 (850-1819) 884 (707-1401) 1123 (849-1719)
P=0.04 P=0.04 P=0.20
In all three pairwise comparisons, the same 31 ET patients with available sampling within 1 year of diagnosis were divided into dichotomous subgroups, according to CALR muta-
tional load. The following CALR mutational load cut-off values were chosen: (i) 34.6%: median CALRmut load of all ET patients excluding cases with myelofibrotic-transformation;
(ii) 38.5%: median CALRmut load of all ET patients; (iii) median CALRmut load of all MPN (ET and PMF all included) patients in the present study. P values represent pairwise com-
parisons between dichotomously divided subgroups of patients (Mann-Whitney test). P values below 0.05 are considered statistically significant and are indicated in bold. ET: essen-
tial thrombocythemia.
JAK2mut patients (P=0.011).
With respect to transformation of ET to myelofibrosis,
we observed a more than 2-fold higher transformation
rate among CALRmut patients (15%) compared to JAK2mut
patients (6%, P=0.034), the rate in the former being similar
to that in the cohort of patients with PV (13%). Nangalia
et al. also found an increased risk of transformation to
myelofibrosis (19% in CALRmut versus 2% in JAK2mut
patients; P=0.03) in a smaller cohort of patients with ET.9
In a large study, the incidence of myelofibrotic transforma-
tion was 7% (95% CI 3-13) in CALRmut versus 5% (95% CI
3-8) in JAK2mut ET versus 8% (95% CI 5-12) in JAK2mut PV,
while the 15-year cumulative incidence of myelofibrotic
transformation was 13.4% (CI 95% 5.4-25.2%) in CALRmut
versus 8.4% (CI 95% 3.9-15.3%) in JAK2mut ET versus
13.6% (CI 95% 7.3-21.9%) in JAK2mut PV (P=not signifi-
cant).12 In our cohort, the median follow-up tended to be
longer in the CALRmut ET group (8 years in CALRmut versus 4
years in JAK2mut; P=0.09), which might have resulted in a
higher frequency of myelofibrotic transformation.
Among patients with ET, we did not find differences in
overall survival according to the presence of a specific
driver mutation. In contrast, Klampfl et al. observed better
survival in patients with CALRmut than in those with
JAK2mut (P=0.04).8 Interestingly, analyzing a larger ET
cohort with substantial overlap with that of Klampfl et al.,
in univariate analysis, Rumi et al. found only a trend
(P=0.085) towards a better overall survival at 15 years for
CALRmut patients compared to JAK2mut patients, and the
trend disappeared when age was considered as a covari-
ate.12 Similarly, Rotunno et al. did not find any difference
in overall survival among patients with ET.11
As for patients with ET and in previous reports,8,13
younger age at disease onset and elevated platelet counts
were found to characterize our CALRmut PMF cohort. Our
observations in PMF were in good agreement with previ-
ous reports,8,13 indicating a significant beneficial effect of
the presence of CALRmut, compared to JAK2mut, on overall
survival. In our dataset, the differences were further sub-
stantiated by pairwise comparisons in a multivariate (with
age added as a covariate) Cox model indicating a trend
towards better survival in CALRmut patients compared to
JAK2mut ones and a significantly better survival between
CALRmut and triple-negative PMF patients. In addition, the
decreased leukemia-free survival in triple-negative PMF
patients reported by Tefferi et al.13 was in line with the
increased rate of acute leukemic transformation in our
triple-negative PMF cases (Table 2). Recently, a set of gene
mutations were described as detrimental in PMF. The
presence of any “high molecular risk” mutations affecting
ASXL1, EZH2, SRSF2, and IDH1/2 genes predicted shorter
overall survival and increased risk of leukemic transforma-
tion. A CALR mutation proved to be an independent pro-
tective factor for survival in PMF.24 ASXL1 mutations, as
the most frequent detrimental mutations, were reported
to occur with similar frequency in JAK2mut, CALRmut and
triple-negative PMF patients;13 thus, in our PMF-cohort,
the survival benefit observed in the group of CALRmut
patients was unlikely to result from an uneven distribution
of ASXL1mutations. The presence of CALRmut in PMF may
affect prognostication and should be incorporated in the
scoring system, as recently suggested.25,26
Our data regarding the frequencies of type 1 and type 2
CALRmut in ET and in PMF were in good agreement with
those of previous cohorts of patients with ET8-10,12 and
PMF.8,13 The asymmetric distribution of different types of
CALRmut in ET and PMF, i.e. the relatively lower frequency
of type 2 CALRmut in PMF, was in line with data from
Klampfl et al.8 They also observed a lower (21/105, 20%)
relative proportion of type 2 mutant cases among PMF
patients than among those with ET (74/195, 38%). The
profound differences in the CALR protein structure may
explain this asymmetric distribution and may imply slight
differences in the pathogenic effects of the respective vari-
ants. The observed asymmetric distribution prompted us
to systematically analyze clinical and outcome differences
in ET patients according to CALRmut type, with the key
findings being older age at diagnosis, higher platelet
counts and more frequent use of cytoreductive therapy in
patients with type 2 CALRmut compared to type 1 or non-
type 2 CALRmut. To our knowledge, similar data in ET have
not been published yet. In line with our data in ET, very
recently Tefferi et al.27 observed distinct characteristics in
PMF in the context of CALR type 2 mutations and EZH2,
IDHmutations, leukocytosis, and peripheral blast percent-
age. Univariate survival analysis suggested a less favorable
outcome in the presence of type 2 CALR mutations.27
These differences may indicate a distinct pathomech-
anism related to insertion or deletion type CALR muta-
tions.
The systematic analyses of CALRmut load in several MPN
subgroups indicated higher CALRmut load compared to
JAK2mut load in ET. In contrast to the JAK2mut load, the
CALRmut load rarely exceeded 50%, indicating a decreased
tendency of the CALRmut locus to undergo mitotic recom-
bination. Uniparental disomy was reported to be less fre-
quent at the CALR locus (19p13.3-p13.2) than at the JAK2
locus (9p24). Using an alternative quantitative PCR tech-
nique, we are in the process of addressing the observation
that CALRmut load may be higher at diagnosis in type 1
CALRmut carriers than in type 2 carriers. Our results indi-
cate that the mutational load of CALRmut resembled that of
JAK2mut in that there was a clear trend towards increased
load in parallel with the appearance of more severe phe-
notypes of MPN. Campbell et al.28 suggested that JAK2
V617F mutated ET, PV and post-ET/PV-myelofibrosis or
PMF form a biological continuum, in which the different
MPN phenotypes are determined by JAK2 V617F allele
burden modified by other environmental and inherited
factors. The increasing JAK2 V617F allele burden through
ET-PV-myelofibrosis phenotypes was later confirmed in
several studies,29-31 and also in a transgenic mouse model.32
Our study shows, for the first time, that hematologic lab-
oratory parameters (white blood cell count, hemoglobin
concentration, platelet count) were directly influenced by
CALR mutational burden in ET patients with samples
available within 1 year of diagnosis. Similarly to JAK2mut
MPN, CALRmut ET and PMF also show overlapping clinical
features, suggesting that the common molecular basis rep-
resents a biological continuum between CALRmut ET and
CALRmut myelofibrosis, in which the clinical phenotype is
modified by the actual CALR mutational load.12
In summary, analyzing a relatively large, independent
cohort of MPN patients, we confirmed recent observa-
tions that the presence of CALR mutations is responsible
for the development of a distinct clinical phenotype in
both ET and PMF. These distinctive features manifest as
different clinical characteristics at diagnosis, different pat-
terns of complications as well as significant differences in
overall survival. Our data supplement and extend previous
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observations regarding the distribution of various types of
CALRmut and associations with different quantities of
CALRmut. Our study shows, for the first time, that hemato-
logic laboratory parameters are directly influenced by
CALRmutational burden. The recent discovery of somatic
CALR mutations not only improves the precision of non-
invasive diagnostics of patients with MPN, but may influ-
ence prognosis and therapy.
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